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Two hundred forty consecutive patients with acute 
myocardial infarction treated within 48 hours by 
successful percutaneous transluminal coronary 
angioplasty (PTCA) were analyzed to determine the 
incidence and predictors of recurrent ischemic 
events during hospitalization. Thirty-nine patients 
had recurrent ischemia: 20 patients had chest pain 
or electrocardiographic changes requiring repeat 
PTCA or bypass surgery, or resulting in a second 
creatine kinase elevation suggestive of myocardial 
infarction; 12 had total occlusion of the dilated ar- 
tery on follow-up angiography; and 7 had exercise- 
induced ischemia and 270% diameter stenosis that 
required PTCA or bypass surgery before hospital 
discharge. In-hospital mortality was 15% in the re- 
current ischemia group, compared to 1% in the 
group without recurrent myocardial ischemia (p 
<O.OOl). Angiographic follow-up before hospital 
discharge was obtained in 198 patients, including 
38 of the 39 patients with ischemic events. Thus, 
the true incidence of recurrent ischemic events was 
between 39 of 199 and 39 of 240, or 16 and 20%. 
In multivariate analyses, recurrent ischemia was 
predicted by translesional gradient >25 mm Hg (p 
= O.OOl), dissection (p = 0.01) and post-PTCA 
Thrombolysis in Myocardial Infarction 2 flow pat- 
tern (p = 0.016). However, even in the absence of 
these risk factors recurrent ischemic events oc- 
curred in 13% of patients. Post-PTCA percent di- 
ameter stenosis (whether assessed by objective or 
visual assessment), degree of the early systemic fi- 
brinolytic state, post-PTCA residual minimal diam- 
eter and concomitant use of thrombolytic agents 
were not predictive. Thus, recurrent ischemia after 
successful PTCA for acute myocardial infarction 
occurs in 16 to 20% of patients, is significantly 
more common with post-PTCA translesional gradi- 
ent 225 mm Hg, dissection or Thrombolysis in 
Myocardial Infarction 2 flow, but may also occur 
unpredictably. 
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P ercutaneous transluminal coronary angioplasty (PTCA), whether performed as primary therapy for patients with contraindication to thrombolysis 
or as an adjunct to failed thrombolytic therapy, can re- 
store artery patency in 83 to 93% of patients with acute 
myocardial infarction (AMI).le5 However, recurrent is- 
chemia before hospital discharge has been reported in 5 
to 3 1% of these patients. 3&j~7 The predictors of recur- 
rent ischemic events have not been described except in 
small series of patients.1,8-‘1 To define a successful 
PTCA result, and to assist in the anticipation of recur- 
rent myocardial ischemia in selected patients, we retro- 
spectively analyzed the in-hospital course of 240 consec- 
utive patients who had AM1 treated with successful 
PTCA for the correlates of recurrent myocardial ische- 
mic events. 
METHODS 
Patients: All patients with AMI treated within 48 
hours by PTCA at the University of Michigan from 
January 1985 until December 1986 with final percent 
stenosis of <70% by quantitative coronary arteriogra- 
phy and final Thrombolysis in Myocardial Infarction 
flow grade 1212 were considered for this analysis. We 
used this broad and previously used3 definition of suc- 
cess to provide a spectrum of results so that a functional 
definition of success might be determined. We were also 
aware of concern that previous reports using visual esti- 
mation of percent stenosis may have overestimated the 
degree of artery opening after PTCA. Patients were ex- 
cluded only if the procedural cineangiograms were un- 
available for review (n = 31), or if the pre- or postdila- 
tation cineangiogram was of insufficient quality to allow 
for quantitative analysis (usually because the angio- 
graphic guidewire was still placed across the lesion at 
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TABLE I Patient and Stenosis Characteristics 
Patients (n = 199) 
Age Ws)* 56 f 10 
Gender (% men) 78 
Time to PTCA (hrs) median (range) 4.3 (14) 
Thrombolytic therapy (%) 59 
Vessels (n = 211) 
No. of coronary arteries dilated (%) 




Pre-PTCA % diameter stenosis* 
Post-PTCA % diameter stenosis* 
Pre-PTCA TIMI flow grade* 
Post-PTCA TIMI flow grade* 
Pre-PTCA translesional gradient (mm Hg)*lt 
Post-PTCA translesional gradient (mm Hg)*zt 
Post-PTCA dissection (%) 
* Mean f standard deviation. 






40 i 13 
1.4 f 1.3 
2.8 f 0.5 
46 f 16 
lOTk9 
7 
the time of the final cineangiogram) (n = 11). Based on 
in-hospital mortality, incidence of emergency bypass 
surgery and clinical characteristics, there was no bias of 
ascertainment induced by nonavailability or inadequate 
quality of cineangiograms. Eighty-two of these patients 
participated in previously reported4,5 or ongoing ran- 
domized trials assessing interventions in AMI. Thus, 
based on randomization, 74 patients also received intra- 
venous recombinant tissue plasminogen activator (150 
mg over 6 to 8 hours) before PTCA, and 8 patients 
received recombinant tissue plasminogen activator and 
urokinase (0.5 to 1.0 million U over 60 minutes) before 
PTCA. In addition, 49 patients received intravenous 
streptokinase (1.0 to 1.5 million U over 30 to 60 min- 
utes) based on clinical indications before PTCA. 
In all patients, PTCA was performed under guide- 
lines approved by this institute’s Committee to Review 
Grants for Clinical Research and Investigation Involv- 
ing Human Beings. Informed consent was obtained 
from every patient before PTCA. 
Indications: Two hundred twenty-four patients un- 
derwent clinically indicated PTCA on the basis of con- 
tinued ischemic chest, neck or arm discomfort or persis- 
tent ST-segment elevation, and 16 patients were ran- 
domized to coronary angioplasty after apparently 
successful thrombolysis without apparent ongoing ische- 
mia. Patients were not considered for PTCA in the pres- 
ence of left main stenosis 260%, or 170% diameter ste- 
noses of both the proximal left anterior descending and 
the left circumflex coronary arteries, or for distal occlu- 
sions in tortuous vessels not felt to be technically suit- 
able for the procedure. Patients were not necessarily ex- 
cluded because of advanced age or poor left ventricular 
function, but often had primary angioplasty in this in- 
stance because they were excluded from randomized tri- 
als435 using thrombolytic agents. 
Angioplasty technique: The technique of PTCA 
used has been previously described.2 After angioplasty, 
patients were treated with intravenous heparin for 2 to 
10 days, oral aspirin 80 to 600 mg daily, dipyridamole 
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225 mg daily and oral calcium antagonists and nitrates 
as tolerated. Ninety-five patients were also given an in- 
fusion of low molecular weight dextran (40 ml/hr) for 
24 hours. The vascular sheaths were usually left in place 
for 24 hours, at which time if the patient was clinically 
stable, the heparin was stopped for 2 to 3 hours and 
the sheaths were removed. After hemostasis had been 
achieved at the groin puncture site, the heparin infusion 
was resumed. All patients were initially monitored in 
the intensive care unit. Hemodynamic monitoring was 
performed and adjunctive drug therapy was adminis- 
tered as clinically indicated. 
Data review: Clinical and procedural data were pro- 
spectively entered on case report forms at the time of 
catheterization. These forms and patient charts were 
audited by an observer unaware of the quantitative an- 
giographic outcome to assure the completeness and ac- 
curacy of the data. Thirteen clinical variables were re- 
corded: patient age, gender, history of diabetes mellitus, 
prior AM1 location (anterior or inferior/posterior), pri- 
or use of p blockers, prior use of calcium antagonists, 
time from onset of chest pain to initiation of coronary 
angioplasty, prior use of intravenous thrombolytic 
agents, systolic blood pressure on arrival in the cardiac 
catheterization laboratory, dextran use, nadir fibrinogen 
and peak fibrin split products after treatment. 
Angiographic analysis: Quantitative measurements 
of the pre- and post-PTCA percent diameter stenosis 
and the absolute residual minimum diameter after angi- 
oplasty were performed using a previously described 
and validated automated quantitative system13 by an 
experienced angiographer blinded to clinical outcome. 
Pre- and post-PTCA percent stenosis and residual mini- 
mal diameters were reported as mean values from or- 
thogonal projections. Visual assessment of percent di- 
ameter stenosis as assessed during clinical cineangio- 
gram review was also recorded. 
Contrast ventriculograms were analyzed for global 
left ventricular ejection fraction by the area-length 
method (CLC version 6A, VVF analysis, Electronics for 
Medicine). End-diastolic and end-systolic frames were 
selected by a blinded observer and the endocardial bor- 
ders were digitized with the use of a lightpen system.14 
In addition, pre- and post-PTCA infarct arteries 
were assessed by a blinded observer for Thrombolysis in 
Myocardial Infarction flowI and 16 other previously 
defined angiographic or morphologic variables15: artery 
dilated, proximal or nonproximal stenosis location, 
number of diseased arteries (150% diameter stenosis), 
post-PTCA dissection (extraluminal opacity or curvilin- 
ear intraluminal filling defect extending beyond the an- 
atomic limits of the stenosis dilated), post-PTCA tear, 
lesion length to the nearest mm, location of the stenosis 
at an end-diastolic bend 145”, branch point location, 
other stenoses 150% in the artery dilated, the presence 
of contrast staining or a filling defect in the pre- and 
post-PTCA films suggestive of thrombus, collaterals be- 
yond the site dilated, diffuse disease in the artery dilat- 
ed, calcification in the area of the stenosis dilated, ste- 
nosis eccentricity and intermittent arterial patency dur- 








Present Not Present p Value 
Recurrent ischemic events: Recurrent ischemic 
events were defined as the in-hospital occurrence of any 
of the following: recurrent chest pain or electrocardio- 
graphic changes requiring repeat PTCA or bypass sur- 
gery, or resulting in a second creatinine kinase elevation 
suggestive of a myocardial infarction: total occlusion of 
the artery dilated noted on follow-up angiography; and 
exercise-induced ischemia and a 270% diameter steno- 
sis at the dilated site that required PTCA or bypass sur- 
gery before hospital discharge. 
Post-PTCA 14 


































18 24 NS 
Statistical analysis: All data were entered into a re- 
lational database using a SYSTAT software package 
(SYSTAT, Inc.). 
25 17 NS 
Unpaired Student’s t tests and chi-square analyses 
were used to compare continuous and categorical single 
variables with outcome. Multiple stepwise linear regres- 
sion analyses with alpha to enter and remove equals 
0.1S6 were used to test hypotheses regarding the inde- 
pendent effect of variables on outcome. This was per- 
formed 3 times: first, using all patients with ischemia or 
angiographic follow-up; second, using only patients in 
whom the post-PTCA translesional gradient had been 
measured; and third, separating patients by type of ad- 
junctive thrombolytic therapy received. A 2-tailed p val- 
ue 10.05 was considered significant although values of 





* Using only artery sites with associated ischemia or anglographically documented 
patency (n = 211). 
t Using only data from the 94 stenoses for which gradient was recorded. 
* By quantitative coronary arteriography. 
RESULTS 
Patient and stenosis characteristics: The 240 pa- 
tients had dilatations performed at 254 arterial sites 
(Table I). One-hundred ninety-eight patients were re- 
studied by arteriography before hospital discharge, and 
1 patient with only 1 site dilated had recurrent ischemia 
without catheterization. Table I shows the characteris- 
tics of the patients (and stenoses) who had either recur- 
rent ischemia or angiographically documented vessel 
patency before discharge and thus comprise the study 
population. In addition to the data presented in Table I, 
there were 90 (43%) total occlusions, calcium was visi- 
ble in 12% of stenoses and collaterals beyond the site 
dilated had been visualized in 32%. In the stenoses in 
which it could be assessed, 22% of dilatations were per- 
formed at bend points and 28% of dilatations were per- 
formed at branch points. The mean lesion length of the 
stenoses dilated was 2.9 f 3.6 mm. Post-PTCA throm- 
bus was present after 53 dilatations (24%) with a mean 
length, when present, of 2.8 f 6.4 mm. Other stenoses 
250% in the same artery were present in 19% of the 
vessels dilated. 
mia occurred at 25 f 17 hours after PTCA (Table II). 
Nineteen patients had stenoses of 270% documented 
angiographically and 1 patient with overt ischemia was 
not restudied (Table II). At the 5 to lo-day follow-up, 
12 patients had total occlusion and 7 patients had steno- 
ses 270% that were treated with PTCA or bypass sur- 
gery during the hospitalization because of exercise-in- 
duced ischemia. Forty-two patients without overt ische- 
mia did not undergo follow-up angiography. Thus, the 
true incidence of recurrent ischemic events on a per pa- 
tient basis was between 39 of 199 and 39 of 240, or 16 
and 20%. 
As shown in Table II, patients with recurrent ische- 
mia had more repeat PTCAs, more emergency bypass 
surgery and a higher mortality during hospitalization. 
Of patients with recurrent ischemia, 20 had repeat 
PTCA (15 successful), 5 had emergency bypass surgery 
and 4 had elective bypass surgery. There were 6 deaths 
in this group (mortality rate 15%). 
Incidence, timing and ~~~s~~uen~es of recwr~e~~ is- 
emit events: Twenty instances of overt clinical ische- 
Univariate ~~e~icters of re4zurrent ischemic events: 
When all patients with follow-up were considered, 3 
variables were significantly correlated with the recur- 
rent ischemic events in the univariate analyses: post- 
PTCA Thrombolysis in Myocardial Infarction flow 
grade 2 (p = 0.03), dissection (p = 0.04) and post- 
PTCA gradient 125 mm Hg (p = 0.05). Post-PTCA 
percent stenosis, measured either using quantitative cor- 
onary arteriography or visually, post-PTCA minimum 
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TABLE III Selected Univariate Correlates of lschemic 
Events* 
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diameter, post-PTCA gradient 220 mm Hg, pre-PTCA 
thrombus and all other variables were not related to re- 
current ischemic events (Table III). 
Restricting the analysis to stenoses with orthogonally 
measured percent stenosis and residual minimum diam- 
eter (n = 114) did not improve the predictive value of 
either variable for recurrent ischemic events (percent 
stenosis in all patients: t = 0.68, p = 0.49; orthogonally 
viewed stenoses only, t = 0.30, p = 0.77; residual mini- 
mal diameter, all patients, t = -0.06, p = 0.95; orthog- 
onally viewed stenoses, t = 0.12, p = 0.90). Objective 
assessment of post-PTCA stenosis severity consistently 
found pre-PTCA percent stenosis lower (88 f 14 vs 94 
f 9, p <O.OOl) and post-PTCA percent stenosis higher 
(40 f 13 vs 31 f 14, p lO.001) than visual assessment, 
but neither assessment of stenosis severity was a strong 
predictor of recurrent ischemic events. 
studies suggest that PTCA need not be performed im- 
mediately after successful thrombolysis,4 but PTCA 
may be beneficial for patients who fail or have contrain- 
dications to thrombolytic therapy, or who have early re- 
current ischemia after initially successful thromboly- 
sis.lA6 
To determine the incidence and the predictors of re- 
current ischemic events after angioplasty, we analyzed 
240 consecutively treated patients, 198 of whom had 
angiographic follow-up 5 to 10 days after PTCA or at 
the time of ischemia. The incidence of recurrent ische- 
mic events on a per patient basis was between 16 and 
20%, and in-hospital mortality was higher in these pa- 
tients than in those without recurrent ischemic events 
(15 vs l%, p <O.OOl). 
There was no significant difference in the incidence 
of recurrent ischemic events between patients treated 
with long-acting, systemic, fibrinolytic agents (strepto- 
kinase or urokinase) (13 of 67, 19%), short half-life, 
“clot-selective” fibrinolytic agents (tissue plasminogen 
activator) (16 of 58, 28%) or no fibrinolytic agents at all 
(10 of 66, 15%) (chi-square = 3.0, p = 0.22). 
Multivariate predictors of recurrent ischemic 
events: When all sites were analyzed, Thrombolysis in 
Myocardial, Infarction flow grade 2 (coefficient = 
0.028, p = 0.001) and dissection (coefficient = 0.26, p 
= 0.01) were found to be independently correlated with 
recurrent ischemic events (constant = 0.14). When only 
sites with gradients available were analyzed, a gradient 
225 mm Hg was also found to be a significant correlate 
of recurrent ischemic events (coefficient = 0.60, p = 
0.001). 
The predictors of recurrent ischemic events after 
PTCA in this setting have not been evaluated in a com- 
prehensive manner using quantitative arteriography. Si- 
mari et allo analyzed 142 patients treated in this setting 
but they did not use quantitative arteriography. Early 
reocclusion occurred in 13% of patients, and was inde- 
pendently correlated with time to PTCA >4 hours, pre- 
PTCA thrombus, post-PTCA dissection, patient age, 
post PTCA Thrombolysis in Myocardial Infarction flow 
grade, left anterior descending or right coronary PTCA 
and “irregular borders” after PTCA.‘O In smaller series 
of patients, but using quantitative techniques, Dean et 
al9 found reocclusion to be related to post-PTCA diam- 
eter stenosis and Thrombolysis in Myocardial Infarction 
flow grade. Grilles et al” found that post-PTCA diame- 
ter stenosis >50% predicted either recurrent ischemia or 
an abnormal early exercise test result. Neither of these 
smaller series used multivariate testing. 
For patients not receiving thrombolytic therapy, 
post-PTCA dissection (coefficient = 0.38, p = 0.002), 
post-PTCA Thrombolysis in Myocardial Infarction flow 
2 (coefficient = 0.32, p = 0.003), and gradient 225 
mm Hg (coefficient = 0.93, p = 0.001) predicted recur- 
rent ischemia with a constant of 0.12. For patients 
treated with either intravenous streptokinase or uroki- 
nase, post-PTCA thrombus (coefficient = 0.37, p = 
0.03) and post-PTCA Thrombolysis in Myocardial In- 
farction flow 2 (coefficient = 0.39, p = 0.04) predicted 
recurrent ischemia with a constant of 0.27. For patients 
treated with intravenous tissue plasminogen activator, 
pre-PTCA Thrombolysis in Myocardial Infarction flow 
grade 2 predicted recurrent ischemia (coefficient = 
0.25, p = 0.03) with a constant of 0.09. Within the high 
risk group (Thrombolysis in Myocardial Infarction flow 
grade 2), only a gradient 125 mm Hg was a predictor 
of recurrent ischemic events (p = 0.006). 
In this study, 3 of the 34 variables tested were inde- 
pendently correlated with recurrent ischemic events: 
post-PTCA Thrombolysis in Myocardial Infarction flow 
2, post-PTCA dissection and post-PTCA translesional 
pressure gradient 225 mm Hg. However, recurrent is- 
chemic events still occurred in 13% of patients without 
these risk factors, and were not predictable by any pre- 
PTCA findings. 
DISCUSSION 
PTCA performed in the setting of AM1 can restore 
arterial patency with efficacy similar to that of the best 
currently available thrombolytic agents,4J2 but recur- 
rent ischemia after angioplasty, as with thrombolytic 
therapy alone,2T4J8-20 is not uncommon.3’4,6,g-1 l Recent 
After thrombolytic therapy alone, without the addi- 
tional vessel injury induced by PTCA, residual minimal 
diameter and percent diameter stenosis have been sug- 
gested as the best predictors of adverse outcome.18-20 
Residual lumen dimension does not appear to be a good 
risk predictor after thrombolysis with tissue plasmino- 
gen activator.21 These factors were not found to be pre- 
dictive in this study. Discordance between flow and 
quantitatively measured percent diameter or area steno- 
sis in the nontraumatized but diseased coronary artery 
is well recognized. 22 The correlation with flow and re- 
sidual minimal diameter is better.22 However, in situ 
thrombus and trauma induced by balloon dilatation 
may impair definition of vessel edges;23 further, PTCA 
may lead to vasoconstriction of adjacent coronary 
sites.24 All of these factors might potentially decrease 
the utility of percent stenosis or residual minimal diam- 
eter to predict outcome. It is not surprising that poor 
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flow, which may indicate a poor PTCA result or high 
distal resistance from the “no reflow phenomenon,“25 
may be a better predictor of subsequent ischemia. 
Dissection and high translesional gradients have pre- 
viously been reported as the most important procedural 
predictors of acute complications after elective coronary 
angioplasty,15 hence their importance in the setting of 
AM1 is not unexpected. Dissection, aside from poten- 
tially compromising flow, is a potent stimulus for 
thrombus formation.26T27 
Limitations: There are 3 potential limitations to this 
study. First, the post-PTCA result was not viewed in 
orthogonal projections in all patients. Measured percent 
diameter stenosis in the right anterior oblique and left 
anterior oblique projections correlated very well in 
Nichols’ study of 10 diagnostic angiograms (r = 0.99)*8 
but correlated poorly in Sanz’s analysis of 13 vessels 
that had undergone PTCA (r = O.O7).23 However, lim- 
iting this analysis to patients with orthogonally viewed 
stenoses did not improve the poor correlation between 
percent stenosis or residual minimal diameter and re- 
current ischemic events. Second, post-PTCA transle- 
sional gradients were not recorded in all patients, and 
clinical judgment may not always exclude “falsely” ele- 
vated gradients, as can be seen with large balloon/ar- 
tery ratios, vasospasm or intermittent thrombus forma- 
tion.29 Finally, the influence of the completeness of pa- 
tient anticoagulation on recurrent ischemia could not be 
assessed. All patients were given antiplatelet agents and 
heparin after PTCA, but activated partial thromboplas- 
tin times temporally proximate (<4 hours) to the time 
of recurrent ischemia were available for only a small 
minority of patients. 
Implications: Recurrent ischemic events after suc- 
cessful PTCA for AM1 are not uncommon, are not al- 
ways predictable and have definite serious adverse con- 
sequences. Close patient monitoring and immediate 
catheterization and surgical availability, especially dur- 
ing the first 24 to 48 hours after PTCA when the risk is 
highest, are mandatory. Patients who have diminished 
coronary flow, high translesional gradient or dissection 
after PTCA, especially if there is a large amount of po- 
tentially viable myocardium at risk, should be consid- 
ered for emergency bypass surgery, and PTCA should 
not be considered complete until an attempt at reducing 
the translesional gradient to <25 mm Hg has been 
made. Finally, improved techniques for maintaining ar- 
tery patency, such as intracoronary stenting30 or anti- 
platelet antibodies31 are needed. 
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